Literature DB >> 34359778

A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma.

Aristea-Maria Papanota1, Panagiotis Tsiakanikas2, Christos K Kontos2, Panagiotis Malandrakis1, Christine-Ivy Liacos1, Ioannis Ntanasis-Stathopoulos1, Nikolaos Kanellias1, Maria Gavriatopoulou1, Efstathios Kastritis1, Margaritis Avgeris2,3, Meletios-Athanasios Dimopoulos1, Andreas Scorilas2, Evangelos Terpos1.   

Abstract

BACKGROUND: Multiple myeloma bone disease (MMBD) constitutes a common and severe complication of multiple myeloma (MM), impacting the quality of life and survival. We evaluated the clinical value of a panel of 19 miRNAs associated with osteoporosis in MMBD.
METHODS: miRNAs were isolated from the plasma of 62 newly diagnosed MM patients with or without MMBD. First-strand cDNA was synthesized, and relative quantification was performed using qPCR. Lastly, we carried out extensive biostatistical analysis.
RESULTS: Circulating levels of let-7b-5p, miR-143-3p, miR-17-5p, miR-214-3p, and miR-335-5p were significantly higher in the blood plasma of MM patients with MMBD compared to those without. Receiver operating characteristic curve and logistic regression analyses showed that these miRNAs could accurately predict MMBD. Furthermore, a standalone multi-miRNA-based logistic regression model exhibited the best predictive potential regarding MMBD. Two of those miRNAs also have a prognostic role in MM since survival analysis indicated that lower circulating levels of both let-7b-5p and miR-335-5p were associated with significantly worse progression-free survival, independently of the established prognostic factors.
CONCLUSIONS: Our study proposes a miRNA signature to facilitate MMBD diagnosis, especially in ambiguous cases. Moreover, we provide evidence of the prognostic role of let-7b-5p and miR-335-5p as non-invasive prognostic biomarkers in MM.

Entities:  

Keywords:  MMBD diagnosis; blood plasma; circulating miRNA; hematological malignancies; molecular biomarker; multiparametric model; osteolysis; prognosis; qPCR; skeletal-related events

Year:  2021        PMID: 34359778     DOI: 10.3390/cancers13153877

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

1.  The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently.

Authors:  Bei Zhang; Bingyang Bian; Yanjiao Zhang; Li Zhang; Rongkui Zhang; Jiping Wang
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

2.  A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma.

Authors:  Aristea-Maria Papanota; Paraskevi Karousi; Christos K Kontos; Pinelopi I Artemaki; Christine-Ivy Liacos; Maria-Alexandra Papadimitriou; Tina Bagratuni; Evangelos Eleutherakis-Papaiakovou; Panagiotis Malandrakis; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Efstathios Kastritis; Margaritis Avgeris; Meletios-Athanasios Dimopoulos; Andreas Scorilas; Evangelos Terpos
Journal:  Int J Mol Sci       Date:  2021-12-05       Impact factor: 5.923

3.  miR-143 Targeting CUX1 to Regulate Proliferation of Dermal Papilla Cells in Hu Sheep.

Authors:  Tingyan Hu; Sainan Huang; Xiaoyang Lv; Shanhe Wang; Tesfaye Getachew; Joram M Mwacharo; Aynalem Haile; Wei Sun
Journal:  Genes (Basel)       Date:  2021-12-18       Impact factor: 4.096

4.  tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature.

Authors:  Paraskevi Karousi; Aristea-Maria Papanota; Pinelopi I Artemaki; Christine-Ivy Liacos; Dimitrios Patseas; Nefeli Mavrianou-Koutsoukou; Aikaterini-Anna Liosi; Maria-Anna Kalioraki; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Efstathios Kastritis; Meletios-Athanasios Dimopoulos; Andreas Scorilas; Evangelos Terpos; Christos K Kontos
Journal:  Biomedicines       Date:  2021-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.